Maze Therapeutics made CNBC's list of top performing stocks of companies based in San Francisco.
Monday - Friday, 2:00 - 3:00 PM ET
In this article
Maze Therapeutics
has had a great run since its initial public offering in January — and CEO Jason Coloma is hoping that momentum continues as the company works on getting kidney-disease drugs to the market.
Maze Therapeutics, a clinical-stage biopharmaceutical company, made its public debut on the Nasdaq stock exchange on January 31 at $16.12 a share, compared to its IPO price of $16. These days it’s trading above $32.
Rigel Pharmaceuticals has landed on CNBC's list of top performing stocks of companies located in San Francisco.
MBX Biosciences has rallied more than 230% over the past year, but there's room for still more upside from current levels,…
The investment bank upgraded the pharma stock to overweight from equal weight.
The bank initiated the clinical-stage biotechnology firm at a buy rating.
Goldman Sachs sees shares of Biohaven rallying 114% after plunging 72% over the past 12 months.
The stock has soared more than 215% this year despite slides earlier this year.
